肺纤维化的遗传学与基因组学:绘制分子图谱并塑造精准医学
本综述综合了肺纤维化(PF)的遗传学证据,包括罕见变异和常见SNP,其中MUC5B启动子变异显著增加早发和已确诊PF风险。文章讨论了端粒长度、基因-环境交互及多组学在精准医学中的潜力,并指出非欧洲血统人群研究不足等缺口。
要点
- MUC5B启动子变异是显著增加PF风险的常见SNP。
- 端粒缩短与PF进展和死亡相关,涉及TERT、TERC等基因。
- 呼吁在多样人群中应用综合基因检测面板和多基因风险评分。
核心结论
- 遗传因素在肺纤维化病因中起重要作用,精准医学有潜力改善管理。
研究设计与样本
- 本文为最先进综述,综合了肺纤维化遗传学与基因组学研究证据。
主要发现
- MUC5B启动子变异是显著增加早发和已确诊PF风险的常见SNP。
- 端粒长度在PF中常显著缩短,与疾病进展和死亡相关。
- 涉及端粒生物学基因(TERT、TERC)及SFTPC、MUC5B等基因的遗传复杂性。
- 基因表达谱和多组学分析有助于理解发病机制并发现生物标志物。
关键数值与推荐
- MUC5B启动子变异为常见SNP,显著增加早发和已确诊PF风险。
- 端粒长度在PF中常显著缩短,与进展和死亡相关。
临床怎么用
- 临床可考虑综合基因检测面板和多基因风险评分以改善PF管理。
- 需进行临床遗传讨论并关注基因组研究的伦理、法律和社会影响。
局限性
- PF遗传研究中非欧洲血统人群代表性不足。
- 对寻常间质性肺炎/IPF之外的PF表型探索有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent genetic and genomic advancements have elucidated the complex etiology of idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (ILDs), emphasizing the contribution of heritable factors. This state-of-the-art review synthesizes evidence on significant genetic contributors to pulmonary fibrosis (PF), including rare genetic variants and common SNPs. The MUC5B promoter variant is unusual, a common SNP that markedly elevates the risk of early and established PF. We address the utility of genetic variation in enhancing understanding of disease pathogenesis and clinical phenotypes, improving disease definitions, and informing prognosis and treatment response. Critical research gaps are highlighted, particularly the underrepresentation of non-European ancestries in PF genetic studies and the exploration of PF phenotypes beyond usual interstitial pneumonia/IPF. We discuss the role of telomere length, often critically short in PF, and its link to progression and mortality, underscoring the genetic complexity involving telomere biology genes (TERT, TERC) and others like SFTPC and MUC5B. In addition, we address the potential of gene-by-environment interactions to modulate disease manifestation, advocating for precision medicine in PF. Insights from gene expression profiling studies and multiomic analyses highlight the promise for understanding disease pathogenesis and offer new approaches to clinical care, therapeutic drug development, and biomarker discovery. Finally, we discuss the ethical, legal, and social implications of genomic research and therapies in PF, stressing the need for sound practices and informed clinical genetic discussions. Looking forward, we advocate for comprehensive genetic testing panels and polygenic risk scores to improve the management of PF and related ILDs across diverse populations.
引用
- Adegunsoye A, Kropski JA, Behr J, et al. Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024. PMID: 38573068. doi:10.1164/rccm.202401-0238SO
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。